WILSON TROY EDWARD 4

What Happened

• Troy Edward Wilson, President, CEO and Director of Kura Oncology (KURA), exercised stock options on 2026-03-23. The Form 4 reports 6,103 shares acquired at an exercise price of $6.15 for a cash outlay of $37,533.
• The filing also lists 6,103 shares at $0.00 in a separate line associated with the same transaction; the footnotes clarify these entries represent stock options exercised and that the option was fully vested. This is an acquisition (exercise), not a sale.

Key Details

• Transaction date: 2026-03-23; Form 4 filed: 2026-03-25 (appears timely under Form 4 rules).
• Exercise price and value: 6,103 shares @ $6.15 = $37,533 (plus a second line reporting 6,103 shares @ $0.00 related to the derivative conversion).
• Shares owned after the transaction: Not disclosed in the report.
• Footnotes: F1 = stock options exercised; F2 = option fully vested.
• No sale was reported and there is no indication this was a cashless exercise or an immediate disposition of shares.

Context

• For retail investors: this was an option exercise (insider acquiring shares by exercising vested options). Because the filing shows a cash payment ($37,533) and no immediate sale, the insider increased his stock position rather than realizing proceeds.
• Exercises are routine for executives with vested options and do not by themselves indicate a buy/sell signal about future company performance.